Biology Reference
In-Depth Information
In general, strong HIV-speci®c CTL has positively correlated with a decline
or slowing of disease progression as well as a state of better well being in the
individual. The development of AIDS has been linked to a drop in e¨ective
CTL responses. Despite these ®ndings, however, it is still not clear whether
HIV-speci®c CTL play a signi®cant role in containing HIV infection in vivo
and how such an e¨ect is mediated.
REFERENCES
Abdullah N, Greenman J, et al. 1999. The role of monocytes and natural killer cells in mediating
antibody-dependent lysis of colorectal tumour cells. Cancer Immunol Immunother 48: 517±524.
Ada G. 1996. Do cytotoxic T lymphocytes clear some HIV/SIV infections? J Med Primatol 25:
158±162.
Ariyoshi K, Cham F, et al. 1995. HIV-2-speci®c cytotoxic T-lymphocyte activity is inversely related
to proviral load. AIDS 9: 555±559.
Autran B, Hadida F, et al. 1996. Evolution and plasticity of CTL responses against HIV. Curr Opin
Immunol 8: 546±553.
Bailer RT, Holloway A, et al. 1999. IL-13 and IFN-gamma secretion by activated T cells in HIV-1
infection associated with viral suppression and a lack of disease progression. J Immunol 162:
7534±7542.
Bangham CR, Phillips RE. 1997. What is required of an HIV vaccine? Lancet 350: 1617±1621.
Bauer M, Lucchiari-Hartz M, et al. 1997. Structural constraints of HIV-1 Nef may curtail escape
from HLA-B7-restricted CTL recognition. Immunol Lett 55: 119±122.
Belshe RB, Gorse GJ, et al. 1998. Induction of immune responses to HIV-1 by canarypox virus
(ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS
Vaccine Evaluation Group. AIDS 12: 2407±2415.
Berke G. 1989. The cytolytic T lymphocyte and its mode of action. Immunol Lett 20: 169±178.
Bernard NF, Pederson K, et al. 1998. HIV-speci®c cytotoxic T-lymphocyte activity in immunolog-
ically normal HIV-infected persons. AIDS 12: 2125±2139.
Betts MR, Krowka J, et al. 1997. Cross-clade human immunode®ciency virus (HIV )-speci®c cyto-
toxic T-lymphocyte responses in HIV-infected Zambians. J Virol 71: 8908±8911.
Betts MR, Krowka JF, et al. 1999. Human immunode®ciency virus type 1-speci®c cytotoxic T
lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected
long-term survivors. AIDS Res Hum Retroviruses 15: 1219±1228.
Betts MR, Casazza JP, et al. 2000. Putative immunodominant human immunode®ciency virus-
speci®c CD8() T-cell responses cannot be predicted by major histocompatibility complex class
I haplotype. J Virol 74: 9144±9151.
Birk M, Vahlne A, et al. 1998. Nonsynonymous mutations within the human immunode®ciency
virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen
class I molecules. AIDS Res Hum Retroviruses 14: 241±248.
Blomberg K, Hautala R, et al. 1996. Time-resolved ¯uorometric assay for natural killer activity
using target cells labelled with a ¯uorescence enhancing ligand. J Immunol Methods 193: 199±
206.
Borrow P, Lewicki H, et al. 1994. Virus-speci®c CD8
cytotoxic T-lymphocyte activity associated
with control of viremia in primary human immunode®ciency virus type 1 infection. J Virol 68:
6103±6110.
Buseyne F, Burgard M, et al. 1998a. Early HIV-speci®c cytotoxic T lymphocytes and disease pro-
gression in children born to HIV-infected mothers. AIDS Res Hum Retroviruses 14: 1435±1444.
